The biotech company has patented a series of A2A agonists that can be administered through transdermal patches or creams, making them suitable for treating conditions such as arthritis, psoriasis, and diabetic neuropathic pain. They have also developed an A2B adenosine antagonist with improved drug properties for asthma and diabetes. Lewis and Clark Pharmaceuticals has signed agreements for sports injury treatment and is in discussions with multiple pharmaceutical companies for cancer and sickle cell disease. Their products are highly potent and selective, offering enhanced distribution in tissue and penetration of human skin, providing physicians with improved treatment options for autoimmune diseases and other conditions.